Formycon and Bioeq Report MAA Submission to EMA for FYB201 (biosimilar- ranibizumab)
Shots:
- Formycon and Bioeq have submitted MAA for FYB201 (biosimilar referencing Lucentis) to EMA
- Teva will responsible for the commercialization of FYB201 in the EU which has acquired the distribution rights under its collaboration with Bioeq. Currently- Formycon has four biosimilars in development
- Formycon focuses to treat ophthalmology- immunology- and other key chronic diseases covering the entire value chain from technical development to the clinical P-III & preparing the data for marketing approval
| Ref: Formycon | Image: Formycon
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com